Incannex Healthcare (IXHL) Stock Price, News & Analysis

Company Overview

Incannex Healthcare Limited (NASDAQ: IXHL) is an Australia-based clinical-stage pharmaceutical company developing cannabinoid- and psychedelic-assisted therapies for conditions with significant unmet medical needs. The company’s research programs are focused on areas including sleep disorders, pain, inflammation, mental health and traumatic brain injury.

Incannex’s lead programs have included IHL-42X, an investigational combination therapy being developed for obstructive sleep apnea, and IHL-675A, a cannabinoid-based therapy studied for inflammatory conditions. The company has also pursued psychedelic-assisted treatment approaches for conditions such as post-traumatic stress disorder and traumatic brain injury. These products remain investigational and are subject to clinical testing and regulatory approval.

Founded in Australia, Incannex conducts development activities in Australia and the United States and has sought to advance its therapies through clinical trials and regulatory pathways in both markets. The company is led by Chief Executive Officer and Managing Director Joel Latham.

Key Stats

• Today's Range: $2.50 to $2.62
• 50-Day Range: $2.52 to $3.80
• 52-Week Range: $2.49 to $14.91
• Volume: 102,452 shs
• Average Volume: 61,795 shs
• Market Capitalization: $31.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Reduce

Incannex Healthcare Stock Analysis - MarketRank™

Incannex Healthcare scored higher than 55% of companies evaluated by MarketBeat, and ranked 486th out of 896 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Incannex Healthcare has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 2 sell ratings.

Upside Potential

Incannex Healthcare has a consensus price target of $18.00, representing about 614.3% upside from its current price of $2.52.

Amount of Analyst Coverage

Incannex Healthcare has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Incannex Healthcare are expected to decrease in the coming year, from ($2.63) to ($2.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Incannex Healthcare is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Incannex Healthcare is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Incannex Healthcare has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.33% of the float of Incannex Healthcare has been sold short.

Short Interest Ratio / Days to Cover

Incannex Healthcare has a short interest ratio ("days to cover") of 6.58.

Change versus previous month

Short interest in Incannex Healthcare has recently decreased by 9.76%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Incannex Healthcare does not currently pay a dividend.

Dividend Growth

Incannex Healthcare does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Incannex Healthcare has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Incannex Healthcare this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for IXHL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added Incannex Healthcare to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Incannex Healthcare insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.33% of the stock of Incannex Healthcare is held by insiders.

Percentage Held by Institutions

0.43% of the stock of Incannex Healthcare is held by institutions.

Company Calendar

• Last Earnings: 9/26/2026
• Today: 10/31/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:IXHL
• CIK: 1873875
• Web: www.incannex.com
• Phone: +61409840786
• Fax: N/A
• Employees: 12
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Incannex Healthcare: $18.00
• High Price Target: $18.00
• Low Price Target: $18.00
• Potential Upside/Downside: +614.3%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.30 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -25.62%
• Return on Assets: -24.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 48.81
• Quick Ratio: 48.81

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.63 per share
• Price / Book: 0.45

Miscellaneous

• Outstanding Shares: 12,545,000
• Free Float: 12,378,000
• Market Cap: $31.61 million
• Optionable: Optionable
• Beta: 6.97